ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

This is not a single experiment but a comprehensive clinical practice guideline. The authors systematically reviewed existing randomised controlled trials, observational studies, and meta-analyses to answer several clinical questions:

Does glucose-lowering therapy (metformin, sulfonylureas, insulin, GLP-1 agonists, DPP-4 inhibitors, SGLT2 inhibitors) reduce cardiovascular events in people with type 2 diabetes?

Does blood pressure lowering (targets <130/80 mmHg vs. <140/90 mmHg) reduce cardiovascular mortality and morbidity?

Does lipid-lowering therapy (statins, fibrates, ezetimibe) reduce cardiovascular events in diabetic populations?

Does antiplatelet therapy (aspirin, clopidogrel) prevent primary or secondary cardiovascular events?

Do lifestyle interventions (diet, physical activity, weight loss) improve cardiovascular outcomes?

What is the optimal screening strategy for detecting undiagnosed diabetes or pre-diabetes in cardiovascular patients?

The comparators were typically placebo, standard care, or less intensive treatment targets. The primary outcome was a composite of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). Secondary outcomes included all-cause mortality, hospitalisation for heart failure, revascularisation, and microvascular complications (nephropathy, retinopathy, neuropathy).

The guideline synthesises data from dozens of trials involving hundreds of thousands of participants. Key populations included:

**General diabetes population:** Adults (mean age 55–70 years) with type 2 diabetes, both with and without established cardiovascular disease. Sample sizes ranged from ~1,000 to ~27,000 per trial.

**Pre-diabetes population:** Adults with impaired fasting glucose (IFG: 5.6–6.9 mmol/L or 100–125 mg/dL) or impaired glucose tolerance (IGT: 2-hour glucose 7.8–11.0 mmol/L or 140–199 mg/dL during OGTT). Trials like the Diabetes Prevention Program (DPP) included ~3,200 participants.

**Cardiovascular disease patients:** People with established coronary artery disease, cerebrovascular disease, or peripheral artery disease, with or without known diabetes. The EUROASPIRE surveys included ~8,000 patients across Europe.

**Specific subgroups:** Elderly (>75 years), those with chronic kidney disease (eGFR <60 mL/min/1.73m²), and those with heart failure.

The guideline explicitly notes that most trial populations were predominantly white (70–90%), with underrepresentation of South Asian, African, and Hispanic populations who have higher diabetes prevalence and different cardiovascular risk profiles.

The guideline used standardised clinical and laboratory measurements:

**Glycaemic control:** Fasting plasma glucose (FPG, mmol/L or mg/dL), HbA1c (%, measured by HPLC or immunoassay, target <7.0% or <53 mmol/mol for most adults), and oral glucose tolerance test (OGTT, 75g glucose load, 2-hour glucose).

**Blood pressure:** Office blood pressure (systolic and diastolic, mmHg, measured by mercury sphygmomanometer or automated device, mean of 2–3 readings after 5 minutes seated rest). Some trials used 24-hour ambulatory blood pressure monitoring.

**Lipids:** Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides (mmol/L or mg/dL, measured by enzymatic methods).

**Cardiovascular outcomes:** MACE (adjudicated by blinded committees), all-cause mortality, hospitalisation for heart failure, revascularisation (PCI or CABG), stroke (ischaemic or haemorrhagic), and peripheral artery events.

**Microvascular outcomes:** Albuminuria (urinary albumin-to-creatinine ratio, mg/g), estimated glomerular filtration rate (eGFR, mL/min/1.73m²), retinopathy (graded by fundus photography), neuropathy (monofilament test or nerve conduction studies).

**Safety outcomes:** Hypoglycaemia (severe: requiring assistance; non-severe: self-treated), weight change (kg), gastrointestinal side effects, and drug-specific adverse events (e.g., pancreatitis with GLP-1 agonists, genital infections with SGLT2 inhibitors).

**Study design:** This is a clinical practice guideline, not a primary research study. The Task Force (experts from the European Society of Cardiology and the European Association for the Study of Diabetes) conducted a systematic literature search of MEDLINE, EMBASE, and the Cochrane Library from 2000 to 2013. They graded evidence using the ESC's standard system (Class I, IIa, IIb, III recommendations with Levels of Evidence A, B, C).

**Evidence synthesis:** The authors did not perform a new meta-analysis. Instead, they summarised existing meta-analyses and landmark trials. For example:

The UK Prospective Diabetes Study (UKPDS, n=5,102, 10-year follow-up) showed that intensive glucose control (sulfonylurea or insulin vs. diet) reduced any diabetes-related endpoint by 12% (HR 0.88, 95% CI 0.79–0.99, p=0.029) and microvascular endpoints by 25% (HR 0.75, 95% CI 0.60–0.93, p=0.0099).

The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (n=10,251, 3.5-year follow-up) tested intensive glucose control (target HbA1c <6.0%) vs. standard control (target 7.0–7.9%). It was stopped early due to increased all-cause mortality in the intensive arm (HR 1.22, 95% CI 1.01–1.46, p=0.04), with 257 deaths vs. 203 deaths.

The Heart Protection Study (HPS, n=20,536, 5-year follow-up) tested simvastatin 40 mg vs. placebo in high-risk patients, including 5,963 with diabetes. It found a 24% reduction in major vascular events (RR 0.76, 95% CI 0.72–0.81, p<0.0001), with similar benefit in those with and without diabetes.

**What this design can and cannot prove:**

**Can prove:** The guideline provides expert consensus on the strength of evidence for various interventions. It can tell you what the best available evidence says about average treatment effects in populations similar to those studied.

**Cannot prove:** It cannot provide individual-level predictions. The guideline is based on group averages, and your personal response to any intervention may differ. It also cannot prove causality for observational associations (e.g., the link between HbA1c and cardiovascular risk is strong but confounded by diabetes duration, comorbidities, and treatment intensity). The guideline is also limited by the quality of the underlying trials — many had short follow-up (2–5 years), high dropout rates (10–30%), and industry sponsorship.

**Major methodological weaknesses:**

The guideline is now over a decade old (published 2013). Newer trials (EMPA-REG OUTCOME, LEADER, CANVAS, DECLARE-TIMI 58) have since shown cardiovascular benefits of SGLT2 inhibitors and GLP-1 agonists that were not available at the time.

The evidence grading system is subjective and can be influenced by expert opinion.

Many recommendations are based on post-hoc analyses or subgroup findings, which are hypothesis-generating rather than definitive.

The guideline does not address the growing evidence for personalised medicine (e.g., genetic predictors of drug response).

**Glucose control:**

Intensive glucose control (target HbA1c <7.0% or <53 mmol/mol) reduced microvascular complications by 25% (HR 0.75, 95% CI 0.60–0.93, p=0.0099) in UKPDS, but the effect on macrovascular outcomes was not statistically significant during the trial (HR 0.84, 95% CI 0.71–1.00, p=0.052). Long-term follow-up (10 years post-trial) showed a 15% reduction in myocardial infarction (HR 0.85, 95% CI 0.74–0.97, p=0.01) and a 13% reduction in all-cause mortality (HR 0.87, 95% CI 0.79–0.96, p=0.006).

More intensive glucose control (target HbA1c <6.0%) in ACCORD increased all-cause mortality by 22% (HR 1.22, 95% CI 1.01–1.46, p=0.04) with no significant reduction in MACE (HR 0.90, 95% CI 0.78–1.04, p=0.16). Severe hypoglycaemia was 3-fold higher in the intensive arm (10.5% vs. 3.5%, p<0.001).

Metformin was the only glucose-lowering drug associated with reduced cardiovascular mortality in UKPDS (HR 0.64, 95% CI 0.45–0.91, p=0.011) and reduced all-cause mortality (HR 0.73, 95% CI 0.55–0.97, p=0.030).

**Blood pressure control:**

Lowering blood pressure to <130/80 mmHg reduced stroke by 31% (RR 0.69, 95% CI 0.58–0.82, p<0.001) and MACE by 14% (RR 0.86, 95% CI 0.77–0.96, p=0.007) compared to <140/90 mmHg, based on a meta-analysis of 5 trials (n=7,312).

However, the ACCORD BP trial (n=4,733) found no significant reduction in MACE with intensive BP lowering (HR 0.88, 95% CI 0.73–1.06, p=0.20), though stroke was reduced by 41% (HR 0.59, 95% CI 0.39–0.89, p=0.01). Serious adverse events (hypotension, syncope, electrolyte abnormalities) were higher in the intensive arm (3.3% vs. 1.3%, p<0.001).

Renin-angiotensin-aldosterone system (RAAS) inhibitors (ACE inhibitors or ARBs) were recommended as first-line therapy due to renoprotective effects, reducing progression to macroalbuminuria by 30–40% (RR 0.60–0.70, p<0.01 across trials).

**Lipid control:**

Statin therapy reduced MACE by 21% per 1 mmol/L (39 mg/dL) reduction in LDL-cholesterol (RR 0.79, 95% CI 0.77–0.81, p<0.0001) in a meta-analysis of 14 trials (n=18,686 with diabetes). The benefit was consistent regardless of baseline LDL level.

High-intensity statins (atorvastatin 80 mg or rosuvastatin 20–40 mg) reduced MACE by an additional 15% compared to moderate-intensity statins (RR 0.85, 95% CI 0.77–0.95, p=0.003) in the TNT trial (n=10,001, including 1,501 with diabetes).

Fibrates showed a 10% reduction in MACE (RR 0.90, 95% CI 0.82–0.99, p=0.03) in a meta-analysis, but only in those with high triglycerides (>2.3 mmol/L or >200 mg/dL) and low HDL (<1.0 mmol/L or <40 mg/dL).

**Antiplatelet therapy:**

Aspirin (75–100 mg/day) for primary prevention in diabetes reduced MACE by 12% (RR 0.88, 95% CI 0.78–0.99, p=0.03) but increased major bleeding by 55% (RR 1.55, 95% CI 1.23–1.95, p<0.001) in a meta-analysis of 9 trials (n=33,325). The number needed to treat for 5 years to prevent one MACE was 200, while the number needed to harm for one major bleed was 150.

For secondary prevention (patients with established CVD), aspirin reduced MACE by 22% (RR 0.78, 95% CI 0.71–0.86, p<0.0001) with a smaller increase in bleeding (RR 1.29, 95% CI 1.10–1.52, p=0.002).

**Lifestyle interventions:**

The Diabetes Prevention Program (DPP, n=3,234) showed that intensive lifestyle intervention (≥150 minutes/week of physical activity, 7% weight loss) reduced progression from pre-diabetes to type 2 diabetes by 58% (HR 0.42, 95% CI 0.34–0.52, p<0.001) compared to placebo, and by 31% compared to metformin (HR 0.69, 95% CI 0.57–0.83, p<0.001).

Long-term follow-up (10 years) showed that the lifestyle group maintained a 34% reduction in diabetes incidence (HR 0.66, 95% CI 0.56–0.78, p<0.001) despite partial weight regain.

The Look AHEAD trial (n=5,145, 9.6-year follow-up) tested intensive lifestyle intervention (calorie restriction, 175 minutes/week of physical activity) vs. diabetes support and education in overweight/obese adults with type 2 diabetes. It found no significant reduction in MACE (HR 0.95, 95% CI 0.83–1.09, p=0.43), but did show improvements in weight loss (−6.0% vs. −3.5%, p<0.001), fitness, HbA1c (−0.22% vs. −0.11%, p<0.001), and fewer hospitalisations.

**Glucose control:** Reducing HbA1c from 8.0% to 7.0% (a 1% absolute reduction) translates to roughly a 15–25% reduction in microvascular complications over 10 years. For macrovascular outcomes, the benefit is smaller (10–15% reduction) and takes 10+ years to emerge. This is roughly equivalent to preventing 1–2 heart attacks or strokes per 100 people treated for 10 years.

**Blood pressure control:** Lowering systolic BP by 10 mmHg reduces stroke risk by about 30% and MACE by about 15% in people with diabetes. This is a larger effect than glucose control — preventing 3–4 strokes per 100 people treated for 5 years.

**Statin therapy:** A 1 mmol/L (39 mg/dL) reduction in LDL-cholesterol reduces MACE by about 21% over 5 years. For someone with diabetes and a baseline LDL of 3.5 mmol/L (135 mg/dL), taking a moderate-intensity statin would prevent about 3–4 major cardiovascular events per 100 people treated for 5 years.

**Lifestyle intervention:** The 58% reduction in diabetes progression from pre-diabetes is one of the largest effect sizes in preventive medicine. For every 100 people with